SIZE XSSIZE SMSIZE MDSIZE LG

Practical Issues for Clinicians - Session II

Originally presented at HOPA's 13th Annual Conference, March 2017.

Insight into Cytokine Release Syndrome

This session will describe CRS as a potential complication of cancer immune-based therapies, discuss the most common medications associated with CRS, and describe the pathophysiology and clinical manifestation of CRS. The grading of CRS and treatment options will also be discussed.

Learning Objectives

  • Identify medications associated with cytokine release syndrome (CRS).
  • Describe the pathophysiology and clinical manifestations of CRS.
  • Discuss appropriate treatment strategies for CRS.

Speaker

Larry Buie, PharmD BCOP

Larry Buie graduated from the University of North Carolina (UNC) Eshelman School of Pharmacy in Chapel Hill, NC. He completed PGY-1 and PGY-2 oncology residencies at UNC Hospitals, along with a fellowship in oncology at the UNC Eshelman School of Pharmacy. He has worked in a variety of oncology clinical pharmacy positions in the South Carolina College of Pharmacy and UNC Hospitals and is currently a leukemia clinical specialist at Memorial Sloan Kettering Cancer Center in New York City. He is board certified in oncology and is a fellow of the American Society of Health-System Pharmacists.

Activity type

Patient Management & Therapeutics

How Do I Treat Hemophagocytic Lymphohistiocytosis?

HLH is a rare, life-threatening syndrome of the immune system that requires prompt recognition and commencement of treatment. This presentation will review the pathophysiology, classification, and diagnosis of this syndrome. Evidence-based treatment strategies will be reviewed, with a focus on treatment of adults, for which there are currently no guidelines. Case-based examples will be discussed, along with supportive care and future research.

Learning Objectives

  • Recognize the diagnostic criteria for hemophagocytic lymphohistiocytosis (HLH).
  • Identify the current evidence-based treatment strategies for HLH in adults.
  • Describe areas of future research for the treatment of HLH.

Speaker

Erica Hochard, PharmD BCOP

Erica Hochard completed her PharmD degree at the University of Kansas in 2011 and completed a PGY-1 pharmacy practice residency at Lawrence Memorial Hospital in Lawrence, KS., and a PGY-2 oncology pharmacy residency at Moffitt Cancer Center in Tampa, FL. She began her career at the University of Kansas Hospital, where she has been an oncology/hematology clinical pharmacist since 2013. Her primary practice areas include both inpatient and outpatient hematology and stem cell transplantation.

Activity type

Patient Management & Therapeutics

Accreditation Statement

logo acpe

The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 29, 2020.

This activity has been approved for .1 CEU

This course is also included as part of the Best of AC2017 Bundle product.

Release Date: August 31, 2017

Expiration Date: March 29, 2020

Member: $25

Non-Member: $35

Purchase Now

xs
sm
md
lg